PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027

PMV Pharmaceuticals, Inc.

Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.
Net loss $77.7M for FY2025 vs $58.7M in 2024; net cash used in ops $73.6M (vs $51.3M).
R&D expenses $69.9M (up from $58.5M) on rezatapopt trial costs; G&A $16.3M (down from $26.9M).
PYNNACLE Phase 2 enrollment on track; NDA submission for ovarian cancer planned Q1 2027.
Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C positive ovarian cancer; Phase 1 in NEJM.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $77.7 million.

Period: the full year ended December 31, 2025
Net income: Net loss for the year ended December 31, 2025, was $77.7 million
Result: reported results

Exact text from the filing

On March 6, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-095094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.